Development-stage biopharmaceutical company
garnered investor enthusiasm after presenting encouraging preclinical data on its prostate cancer drug candidate HE3235.
According to preclinical models using human tumor cells, the treatment significantly stopped growth in hormone-independent tumors, which are associated with late-stage prostate cancer. Hollis-Eden also presented data that suggested the treatment could potentially trigger tumor cell death.
In addition to HE3235, Hollis-Eden is preparing its HE3286 product for clinical trials in treating type II diabetes and potentially for rheumatoid arthritis.
Shares surged 65 cents, or 32%, to $2.69 Thursday.